Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T18:53:09.411Z Has data issue: false hasContentIssue false
  • English
  • Français

Question-and-Answer Session

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
CNS Spectrums , Volume 15 , supplement S7: Current Evidence and Future Directions: Augmentation and Dosing Strategies for Major Depressive Disorder , June 2010 , pp. 14
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Nelson, JC, Papakostas, G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980–991.CrossRefGoogle ScholarPubMed
2.Shelton, RC, Tollefson, GD, Tohen, M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–134.CrossRefGoogle ScholarPubMed
3.Tohen, M, Case, M, Trivedi, MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71(4):451–462.CrossRefGoogle Scholar